A Phase 2 interventional study of SPG601 and Placebo in Fragile X Syndrome, sponsored by Spinogenix. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Spinogenix · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Fragile X Syndrome with a site in United States — 11 open to participants now, 16 under way, 2 of them phase 3. Fragile X Syndrome · United States.
Among the 82 studies in Fragile X Syndrome with a site in United States, this one is the 62nd largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 in phase 2, and was the 76th registered.
115 studies on the registry are indexed under Fragile X Syndrome; 25 are open to participants now.
Browse Fragile X Syndrome studies →11 of the 82 studies in Fragile X Syndrome with a site in United States are open now. Recruiting first, the newest first:
Healing Hope International · Sites in United States
Ages 4–12
Mirum Pharmaceuticals, Inc. · Sites in United States, Spain
Ages 13–45 · Men only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 5–10 · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo–26 mo · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Fragile X Syndrome studies recruiting now, 5 (28%) set no upper age limit and 13 (72%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 45 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 36 · Phase 3 11 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 54 across 92 interventional studies indexed under Fragile X Syndrome.
Median enrollment 60 across the 68 interventional studies, 100 across the 12 observational. Of the 58 that completed or were terminated, 22 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 82 have an industry lead sponsor. The 10 most frequent:
Spinogenix is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Spinogenix has 2 studies filed under Fragile X Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Fragile X Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05367960Phase 3Tetra Discovery PartnersAn Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | 2027-09-30 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
| NCT06560242Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant | 2027-03-01 |
| NCT05957549Children's Hospital Medical Center, CincinnatiTracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 82 studies in Fragile X Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.
This study is a Phase 2 randomized, double blind, placebo-controlled, cross over, single dose of SPG601 and matching Placebo in patients with Fragile X syndrome.
This study will entail 2 in person clinic visits to administer oral doses of SPG601 or matching placebo. Participants will receive a dose of either SPG601 or placebo at first visit, and will cross over to receive the other product at the second visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.
Drug: SPG601
Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.
Drug: Placebo
synthetic small molecule
Placebo
Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician
Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
Time frame: 15 days
Clinical Global Impressions Improvement Scale as Determined by the Caregiver
Change in caregiver rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
Time frame: 15 days
Visual Analog Scale as Determined by the Patient Caregiver
Change from baseline in notation on Visual Analog scale as determined by the patient caregiver. Rater will indicate on linear measurement scale of 1 to 100 centimeters, with higher score indicating more severe symptoms
Time frame: 15 days
Change in Auditory Response to Chirp Stimulus
Auditory test will be evaluated for difference in responses to stimuli, as demonstrated by the Inter-Trial Coherence (ITC). ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC is a unit of measure as frequency (40Hz) vs time (msec).
Time frame: 15 days
Change From Baseline in Attention and Inhibition Symptoms-Go/NoGo Subtest
KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The Go-NoGo subtest measures impulsivity by requiring subjects to tap a button when the target stimulus is presented, while refraining from hitting the button for the non-target stimulus. Summary statistics presented for change in reaction time from baseline.
Time frame: 15 days
Change in Cognitive Outcomes Measured by NIH Cognitive Toolbox
National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB): A series of tests will be conducted to assess reading, vocabulary, and speed matching. These tests are scored from zero to 100. A higher score indicate better performance.
Time frame: 15 days
Change in Memory and Cognitive Assessment With RBANS List Learning.
RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is scored from -4 to 4, with higher values indicate higher memory and cognitive assessment
Time frame: 15 days
Change in Auditory Response to Steady State Auditory Stimuli From Baseline
Auditory test will be evaluated for difference in responses to stimuli. Auditory Steady State Response (ASSR) is measured following a short stream of click trains with a 500 msec inter-train interval (duration), at standard tone and at 40Hz tone. The magnitude of ITC represents the phase consistency of oscillatory activities. ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC as a unit of measure is expressed as frequency (40Hz) vs time (msec)
Time frame: 15 days
Safety and Tolerability of SPG601 in Patients With Fragile X Syndrome
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: 15 days
Change From Baseline in Attention and Inhibition Symptoms-Flexibility Subtest
The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring different basal as well as higher-order components of attention and executive functioning. The alertness subtest requires subjects to tap a button every time a stimulus appears on the screen. Mean reaction time was measured over 90 seconds and change from baseline was calculated. A lower reaction time (net decrease in reaction time) indicates better performance.
Time frame: 15 days
Change From Baseline in Attention and Inhibition Symptoms-Alertness Subtest
KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The alertness subtest records the number of times a subject taps a button when a stimulus appears on screen. Change in Baseline summary statistics for reaction time presented below. A lower number indicates lower reaction time and better performance.
Time frame: 15 days
Change From Baseline in Attention and Inhibition Symptoms-Distractability Subtest
The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring components of attention and executive functioning. The distractibility subtest measures how easily the subject is distracted by extraneous stimuli. This subtest requires subjects to tap a button when a target stimulus appears on the screen while ignoring distractions. Mean number of correct responses were recorded, and change from baseline was calculated, and a higher mean number of correct responses indicates better performance.
Time frame: 15 days
Change in Eye Tracking for Social Gaze
This test will measure eye tracking and movement in response to stimuli, and social gaze version, with a Likert scale of 1-5 for behavior rating.
Time frame: 15 days
Change in Eye Tracking Measured by Electroretinography
This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-RIGHT EYE
Time frame: 15 days
Change in Eye Tracking Measured by Electroretinography
This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-LEFT EYE
Time frame: 15 days
| Milestone | Sequence 1: SPG601 First, Placebo Second | Sequence 2: Placebo First SPG601 Second |
|---|---|---|
| Started | 5 | 5 |
| Completed | 5 | 5 |
| Not completed | 0 | 0 |
Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
| score on a scale | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician | 3.7 (3.106 to 4.07) | 3.8 (3.399 to 4.26) |
Change in caregiver rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation
| score on a scale | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Clinical Global Impressions Improvement Scale as Determined by the Caregiver | 2.9 (1.1 to 3.6) | 2.8 (1.16 to 3.8) |
Change from baseline in notation on Visual Analog scale as determined by the patient caregiver. Rater will indicate on linear measurement scale of 1 to 100 centimeters, with higher score indicating more severe symptoms
| score on a scale | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Visual Analog Scale as Determined by the Patient Caregiver | -6.5 (-18.61 to 4.408) | -6 (-16.25 to 5.334) |
Auditory test will be evaluated for difference in responses to stimuli, as demonstrated by the Inter-Trial Coherence (ITC). ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC is a unit of measure as frequency (40Hz) vs time (msec).
| Inter Trial Coherence | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change in Auditory Response to Chirp Stimulus | -0.012 ± 0.041 | 0.014 ± 0.062 |
KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The Go-NoGo subtest measures impulsivity by requiring subjects to tap a button when the target stimulus is presented, while refraining from hitting the button for the non-target stimulus. Summary statistics presented for change in reaction time from baseline.
| milliseconds | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change From Baseline in Attention and Inhibition Symptoms-Go/NoGo Subtest | 67.8 (-87.63 to 220.4) | -17.6 (-145.8 to 112.6) |
National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB): A series of tests will be conducted to assess reading, vocabulary, and speed matching. These tests are scored from zero to 100. A higher score indicate better performance.
| score on a scale | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change in Cognitive Outcomes Measured by NIH Cognitive Toolbox | 15.5 (-2.098 to 41.05) | 1.7 (-26.52 to 23.13) |
RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is scored from -4 to 4, with higher values indicate higher memory and cognitive assessment
| score on a scale | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change in Memory and Cognitive Assessment With RBANS List Learning. | 1.7 (-.546 to 3.879) | 3.8 (.7873 to 5.213) |
Auditory test will be evaluated for difference in responses to stimuli. Auditory Steady State Response (ASSR) is measured following a short stream of click trains with a 500 msec inter-train interval (duration), at standard tone and at 40Hz tone. The magnitude of ITC represents the phase consistency of oscillatory activities. ITC is a measure of phase consistency across trials, expressed as a dimensionless value ranging from 0 to 1. A value of 0 indicates completely random phase across trials, while 1 denotes a perfectly phase-locked response across trials. Higher ITC values reflect greater phase consistency of neural oscillations. ITC as a unit of measure is expressed as frequency (40Hz) vs time (msec)
| ITC | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change in Auditory Response to Steady State Auditory Stimuli From Baseline | -0.012 ± 0.0417 | 0.014 ± 0.0615 |
Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
| participants | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Safety and Tolerability of SPG601 in Patients With Fragile X Syndrome | 1 | 0 |
The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring different basal as well as higher-order components of attention and executive functioning. The alertness subtest requires subjects to tap a button every time a stimulus appears on the screen. Mean reaction time was measured over 90 seconds and change from baseline was calculated. A lower reaction time (net decrease in reaction time) indicates better performance.
| milliseconds | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change From Baseline in Attention and Inhibition Symptoms-Flexibility Subtest | -61.8 (-356.6 to 207) | -103.4 (-330.5 to 142.3) |
KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions. The alertness subtest records the number of times a subject taps a button when a stimulus appears on screen. Change in Baseline summary statistics for reaction time presented below. A lower number indicates lower reaction time and better performance.
| milliseconds | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change From Baseline in Attention and Inhibition Symptoms-Alertness Subtest | 129.4 (-142.4 to 402) | -133 (-405.5 to 138.8) |
The KiTAP is a computerized executive function battery that consists of eight nonverbal subtests measuring components of attention and executive functioning. The distractibility subtest measures how easily the subject is distracted by extraneous stimuli. This subtest requires subjects to tap a button when a target stimulus appears on the screen while ignoring distractions. Mean number of correct responses were recorded, and change from baseline was calculated, and a higher mean number of correct responses indicates better performance.
| correct responses | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change From Baseline in Attention and Inhibition Symptoms-Distractability Subtest | -54.7 (-173.6 to 93.29) | 45.94 (-63.14 to 155) |
This test will measure eye tracking and movement in response to stimuli, and social gaze version, with a Likert scale of 1-5 for behavior rating.
No measurements were reported for this outcome.
This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-RIGHT EYE
| milli volts | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change in Eye Tracking Measured by Electroretinography | -1.35 ± 1.78 | -1.15 ± 3.11 |
This test will measure the electrical activity in the retina in response to stimuli, evaluating change in stimuli response post dose minus stimuli pre dose-LEFT EYE
| milli volts | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| Change in Eye Tracking Measured by Electroretinography | -2.16 ± 4.88 | .03 ± 2.05 |
Collected over Adverse event data was collected at study visits that happened weekly for 3 weeks.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Event | Experimental: Active SPG601 to be Administered to Participants With Fragile X Syndrome | Placebo Comparator: Placebo Comparator to be Administered to Participants With Fragile X Syndrome |
|---|---|---|
| exacerbation of ticPsychiatric disorders | 1/10 | 0/10 |
Adult men with Fragile X syndrome; cross-over study and all study participants were randomized to receive active drug or placebo at first study visit, and received other treatment allocation at subsequent study visit
| Age, Categorical(Participants) | The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study. |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 10 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study. |
|---|---|
| Female | 0 |
| Male | 10 |
| Ethnicity (NIH/OMB)(Participants) | The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study. |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | The Study Was a Crossover Trial of Two Treatments Administered at Day 1 and Day 8 of the Study. |
|---|---|
| United States | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2024 to primary completion in Dec 2024, 5 months.
Results were first posted in May 2026, 1 year 4 months after primary completion.
Of 15 phase 2 interventional studies under Fragile X Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spinogenix